How to Apply for a LUNGevity Grant

LUNGevity Awards for Translational Research

LUNGevity supports translational research in three tracks: career development, early detection, and targeted therapeutics.

Read about  funded projects here.

The 2020 Career Development Award program is now closed for application submissions.

Career Development Awards

  • 3-year grants, totaling $300,000
  • Limit of one award per institution
  • Mentored awards

click here for details

Career Development Awards

LUNGevity’s Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas.

Applicants must be within the first five years of their faculty appointment. The Career Development Awards are mentored awards; a mentoring plan is part of the required submission.

Funded projects are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment, including through targeted therapy and immunotherapy.

Early Detection and Interception Award

LUNGevity Foundation has collaborated with Stand Up To Cancer and the American Lung Association (via LUNG FORCE) on two projects that focus on lung cancer interception: catching precancerous cells and blocking them from turning into cancer cells. The Thomas G. Labrecque Foundation has also invested in these collaborations. Two teams of interdisciplinary and multi-institutional researchers have been funded: a Lung Cancer Interception Dream Team, whose project is Intercept Lung Cancer Through Immune, Imaging, & Molecular Evaluation (InTIME) (2018-2022)and a Lung Cancer Interception Translational Research Team, whose project was Blood-Based Early Interception of Lung Cancer (2018-2019). 

Therapeutics Awards

LUNGevity’s Therapeutics Awards for Translational Research support research projects directed at individualized treatments, including targeted therapeutics and immunotherapy, that will make a difference in the clinical treatment and survival of patients.